Perfuse’s PER-001 intravitreal implant receives FDA clearance for first-in-human study in glaucoma
April 5, 2023
Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma.
